AT291228B - Verfahren zur Herstellung neuer α,α-Dimethyl-ω-phenoxyalkansäuren, ihrer Salze oder Alkylester - Google Patents
Verfahren zur Herstellung neuer α,α-Dimethyl-ω-phenoxyalkansäuren, ihrer Salze oder AlkylesterInfo
- Publication number
- AT291228B AT291228B AT782869A AT782869A AT291228B AT 291228 B AT291228 B AT 291228B AT 782869 A AT782869 A AT 782869A AT 782869 A AT782869 A AT 782869A AT 291228 B AT291228 B AT 291228B
- Authority
- AT
- Austria
- Prior art keywords
- dimethyl
- acid
- lower alkyl
- salts
- formula
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims description 17
- 238000000034 method Methods 0.000 title claims description 14
- 150000003839 salts Chemical class 0.000 title claims description 9
- 150000007513 acids Chemical class 0.000 title claims description 6
- 125000005907 alkyl ester group Chemical group 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title claims description 4
- -1 aryloxyalkyl halide Chemical class 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 150000001340 alkali metals Chemical class 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 150000001734 carboxylic acid salts Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 8
- 239000003513 alkali Substances 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 229940043279 diisopropylamine Drugs 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- NIDWUZTTXGJFNN-UHFFFAOYSA-N 3-bromopropoxybenzene Chemical compound BrCCCOC1=CC=CC=C1 NIDWUZTTXGJFNN-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 2
- WDAXFOBOLVPGLV-UHFFFAOYSA-N ethyl isobutyrate Chemical compound CCOC(=O)C(C)C WDAXFOBOLVPGLV-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical class [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- TXEKOXGGVSAZIE-UHFFFAOYSA-N 1,4-ditert-butyl-2-(3-chloropropoxy)benzene Chemical compound C(C)(C)(C)C1=C(OCCCCl)C=C(C=C1)C(C)(C)C TXEKOXGGVSAZIE-UHFFFAOYSA-N 0.000 description 1
- DRFYEIPEKLGMKO-UHFFFAOYSA-N 2-(3-bromopropoxy)-1,4-dimethylbenzene Chemical compound CC1=CC=C(C)C(OCCCBr)=C1 DRFYEIPEKLGMKO-UHFFFAOYSA-N 0.000 description 1
- YRDIWLKDRLFWBP-UHFFFAOYSA-N 2-(3-bromopropoxy)-1-methyl-4-propan-2-ylbenzene Chemical compound CC(C)C1=CC=C(C)C(OCCCBr)=C1 YRDIWLKDRLFWBP-UHFFFAOYSA-N 0.000 description 1
- BHIIOLWIZLICII-UHFFFAOYSA-N 2-butyl-5-methylphenol Chemical compound CCCCC1=CC=C(C)C=C1O BHIIOLWIZLICII-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical group CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- 229940008406 diethyl sulfate Drugs 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- YDGSUPBDGKOGQT-UHFFFAOYSA-N lithium;dimethylazanide Chemical compound [Li+].C[N-]C YDGSUPBDGKOGQT-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- VDUQUWCVENWCNL-UHFFFAOYSA-L magnesium;2-methylpropanoate Chemical compound [Mg+2].CC(C)C([O-])=O.CC(C)C([O-])=O VDUQUWCVENWCNL-UHFFFAOYSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/367—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in singly bound form
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US819126A US3674836A (en) | 1968-05-21 | 1969-04-24 | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
| DE19691925423 DE1925423A1 (de) | 1968-05-21 | 1969-05-19 | 2,2-Dimethyl-omega-aryloxyalkansaeuren und ihre Salze und Ester |
| GB2576069A GB1225575A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1968-05-21 | 1969-05-20 | |
| FR6916281A FR2008997A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1968-05-21 | 1969-05-20 | |
| ZA695769A ZA695769B (en) | 1968-05-21 | 1969-08-12 | New aryloxy compounds and methods for their production |
| AT782869A AT291228B (de) | 1968-05-21 | 1969-08-14 | Verfahren zur Herstellung neuer α,α-Dimethyl-ω-phenoxyalkansäuren, ihrer Salze oder Alkylester |
| NL696912790A NL148872B (nl) | 1968-05-21 | 1969-08-21 | Werkwijze ter bereiding van farmacologisch werkzame omega-aryloxyalkaancarbonzuurderivaten; werkwijze ter bereiding van farmaceutische preparaten en de aldus verkregen gevormde voortbrengselen. |
| BR211856/69A BR6911856D0 (pt) | 1968-05-21 | 1969-08-26 | Processo para a producao de novos compostos ariloxi |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73094668A | 1968-05-21 | 1968-05-21 | |
| US819126A US3674836A (en) | 1968-05-21 | 1969-04-24 | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
| ZA695769A ZA695769B (en) | 1968-05-21 | 1969-08-12 | New aryloxy compounds and methods for their production |
| AT782869A AT291228B (de) | 1968-05-21 | 1969-08-14 | Verfahren zur Herstellung neuer α,α-Dimethyl-ω-phenoxyalkansäuren, ihrer Salze oder Alkylester |
| NL696912790A NL148872B (nl) | 1968-05-21 | 1969-08-21 | Werkwijze ter bereiding van farmacologisch werkzame omega-aryloxyalkaancarbonzuurderivaten; werkwijze ter bereiding van farmaceutische preparaten en de aldus verkregen gevormde voortbrengselen. |
| BR211856/69A BR6911856D0 (pt) | 1968-05-21 | 1969-08-26 | Processo para a producao de novos compostos ariloxi |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AT291228B true AT291228B (de) | 1971-07-12 |
Family
ID=36691343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT782869A AT291228B (de) | 1968-05-21 | 1969-08-14 | Verfahren zur Herstellung neuer α,α-Dimethyl-ω-phenoxyalkansäuren, ihrer Salze oder Alkylester |
Country Status (8)
Families Citing this family (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3971816A (en) * | 1973-11-26 | 1976-07-27 | Ceskoslovenska Akademie Ved | Esters of carboxylic acids formally substituted by sodium or potassium in the alpha-position and the method for their preparation |
| US4012523A (en) * | 1974-01-24 | 1977-03-15 | The Dow Chemical Company | Hypolipidemic 2-(3,5-di-tert-butyl-4-hydroxyphenyl)-(thio or sulfonyl) alkanoic acids and derivatives |
| US4067998A (en) * | 1974-02-11 | 1978-01-10 | The Dow Chemical Company | 2-((3,5-Di-tert-butylphenyl)thio) alkanoic acids and derivatives |
| US4020177A (en) * | 1974-08-30 | 1977-04-26 | Merck & Co., Inc. | Substituted phenoxy-tridecanoic acids |
| US4024182A (en) * | 1975-08-15 | 1977-05-17 | Sandoz, Inc. | Preparation of aryl-butadienoic acids |
| US4126637A (en) * | 1977-06-17 | 1978-11-21 | Warner-Lambert Company | Process for the production of 2,2-dimethyl-5-(2,5-xylyloxy)valeric acid |
| GB2024209B (en) * | 1978-05-31 | 1982-09-08 | Sori Soc Rech Ind | Phenoxalkylcarboxylic acids |
| US4285951A (en) * | 1979-09-07 | 1981-08-25 | Warner-Lambert Company | 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentyl ester of 3-pyridine carboxylic acid and use as an anti-atherosclerotic agent |
| US4351950A (en) * | 1980-01-02 | 1982-09-28 | Warner-Lambert Company | Anti-arteriosclerotic agents |
| US4477556A (en) * | 1982-08-18 | 1984-10-16 | E. I. Du Pont De Nemours And Company | Acidic o-nitroaromatics as photoinhibitors of polymerization in positive working films |
| US4665226A (en) * | 1985-12-09 | 1987-05-12 | Warner-Lambert Company | Process for preparing 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid |
| US4714762A (en) * | 1986-10-31 | 1987-12-22 | Warner-Lambert Company | Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof |
| EP0276807A3 (en) * | 1987-01-27 | 1988-10-12 | Warner-Lambert Company | Lipid regulating compositions |
| US4973731A (en) * | 1987-04-23 | 1990-11-27 | Riker Laboratories, Inc. | Di-t-butylphenyl alkyl and benzyl ether nitriles |
| US4859703A (en) * | 1987-06-15 | 1989-08-22 | Warner-Lambert Company | Lipid regulating compositions |
| US4968710A (en) * | 1987-11-13 | 1990-11-06 | Riker Laboratories, Inc. | Substituted di-t-butylphenols and anti-allergic use thereof |
| US5066822A (en) * | 1987-11-13 | 1991-11-19 | Riker Laboratories, Inc | Di-t-butylphenols substituted by an alkoxy or benzyloxy group or a benzylthio group |
| US5260305A (en) * | 1988-12-12 | 1993-11-09 | E. R. Squibb & Sons, Inc. | Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination |
| HU205891B (en) * | 1990-05-11 | 1992-07-28 | Gyogyszerkutato Intezet | Process for producing 2,2-dimethyl-5-/2,5-dimethyl-phenoxy/-pentanoic acid |
| US5235097A (en) * | 1990-05-11 | 1993-08-10 | Egis Gyogyszergyar | Process for the preparation of 2,2-dimethyl-5-(2,5-dimethyl-phenoxy)-pentanoic acid, intermediates for preparing this compound and process for preparing the intermediates |
| US5041640A (en) * | 1990-09-20 | 1991-08-20 | Warner-Lambert Company | Process for mono-, di-, trisubstituted acetic acids |
| HU212428B (en) * | 1994-05-13 | 1996-06-28 | Egyt Gyogyszervegyeszeti Gyar | Process to prepare pharmaceutical compositions containing gemfibrozyl |
| US5530145A (en) * | 1994-06-14 | 1996-06-25 | Syn-Tech Chem & Pharm Co., Ltd. | Anticholesteremic compounds |
| US5412112A (en) * | 1994-06-14 | 1995-05-02 | Industrial Technology Research Institute | Derivatives and preparation of 2,2-dimethyl-5-substituted phenoxy-pentanoic acids |
| US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| US6268392B1 (en) | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
| IT1274355B (it) * | 1994-12-21 | 1997-07-17 | Alfa Wassermann Spa | Lattoni ad attivita' antiossidante ed ipolipidemica utili nella terapia dell'aterosclerosi |
| DE4446387A1 (de) * | 1994-12-23 | 1996-06-27 | Basf Ag | Verfahren zur Herstellung fester, freifließender wasserlöslicher Salze von Aryloxi-C¶1¶-C¶4¶-alkancarbonsäuren |
| US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| US6713043B2 (en) * | 1996-02-29 | 2004-03-30 | The Trustees Of Columbia University In The City Of New York | Antimicrobial activity of gemfibrozil |
| US5883109A (en) * | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| EP0989852A4 (en) * | 1997-01-17 | 2002-11-13 | Bristol Myers Squibb Co | METHODS FOR TREATING ATHEROSCLEROSE THROUGH AN MPT INHIBITOR AND CHOLESTEROL LEVELS LOWERING MEDICINES |
| AU748608B2 (en) * | 1997-05-01 | 2002-06-06 | Bristol-Myers Squibb Company | MTP inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels |
| US20010006644A1 (en) | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
| US6469035B1 (en) * | 1997-07-31 | 2002-10-22 | Eugenio A. Cefali | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
| US6083497A (en) * | 1997-11-05 | 2000-07-04 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers |
| US6264960B1 (en) | 1998-11-10 | 2001-07-24 | Sander J. Robins | Treatment of vascular events using lipid-modifying compositions |
| IL143946A0 (en) * | 1998-12-23 | 2002-04-21 | Searle Llc | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein for cardiovascular indications |
| CA2356607A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
| US6462091B1 (en) | 1998-12-23 | 2002-10-08 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications |
| EP1140184B1 (en) * | 1998-12-23 | 2003-06-04 | G.D. Searle LLC. | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| AU2157500A (en) | 1998-12-23 | 2000-07-31 | G.D. Searle Llc | Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications |
| JP2002533410A (ja) * | 1998-12-23 | 2002-10-08 | ジー．ディー．サール エルエルシー | 心臓血管に適用するためのコレステリルエステル転送タンパク質阻害剤およびフィブリン酸誘導体の組み合わせ |
| CN1338945A (zh) * | 1998-12-23 | 2002-03-06 | G·D·瑟尔有限公司 | 适用于心血管疾病的回肠胆汁酸转运抑制剂和胆汁酸螯合剂组合 |
| AU779264B2 (en) * | 1998-12-23 | 2005-01-13 | G.D. Searle Llc | Combinations for cardiovascular indications |
| US7129274B1 (en) | 1999-11-05 | 2006-10-31 | Emisphere Technologies Inc. | Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| US7279597B1 (en) | 1999-11-05 | 2007-10-09 | Emisphere Technologies, Inc. | Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| WO2001068637A2 (en) | 2000-03-10 | 2001-09-20 | Pharmacia Corporation | Method for the preparation of tetrahydrobenzothiepines |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| US20020061888A1 (en) * | 2000-03-10 | 2002-05-23 | Keller Bradley T. | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
| WO2003079972A2 (en) | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| DK1385856T3 (da) | 2001-04-11 | 2006-05-15 | Bristol Myers Squibb Co | Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder |
| US20040077625A1 (en) * | 2001-07-25 | 2004-04-22 | Tremont Samuel J. | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake |
| US7238671B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| IL160917A0 (en) * | 2001-10-18 | 2004-08-31 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| US6806381B2 (en) * | 2001-11-02 | 2004-10-19 | Bristol-Myers Squibb Company | Process for the preparation of aniline-derived thyroid receptor ligands |
| BR0213501A (pt) * | 2001-11-02 | 2004-08-24 | Searle Llc | Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato |
| WO2003043624A1 (en) * | 2001-11-16 | 2003-05-30 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
| US6852753B2 (en) | 2002-01-17 | 2005-02-08 | Pharmacia Corporation | Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake |
| ZA200407802B (en) * | 2002-03-20 | 2006-11-29 | Metabolex Inc | Substituted phenylacetic acids |
| AU2003225102A1 (en) * | 2002-04-23 | 2003-11-10 | Bristol-Myers Squibb Company | Modified-release vasopeptidase inhibitor formulation, combinations and method |
| WO2003096548A2 (de) * | 2002-05-14 | 2003-11-20 | Siemens Aktiengesellschaft | Verfahren zum erzeugen eines sendesignals |
| US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| EP1553937B1 (en) * | 2002-10-23 | 2010-06-02 | Bristol-Myers Squibb Company | Glycinenitrile-based inhibitors of dipeptidyl peptidase iv |
| US7098235B2 (en) * | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
| AU2004242777B2 (en) * | 2003-05-30 | 2011-05-12 | Ranbaxy Laboratories Limited | Substituted pyrrole derivatives and their use as HMG-Co inhibitors |
| WO2004108126A1 (en) * | 2003-06-06 | 2004-12-16 | Snowden Pharmaceuticals, Llc | Fibric acid derivatives for the treatment of irritable bowel syndrome |
| US7459474B2 (en) * | 2003-06-11 | 2008-12-02 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
| US7199259B2 (en) * | 2003-06-20 | 2007-04-03 | Metabolex, Inc. | Resolution of α-(phenoxy)phenylacetic acid derivatives |
| US6995183B2 (en) * | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
| US7371759B2 (en) * | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| EP1680099B1 (en) * | 2003-11-07 | 2009-04-15 | JJ Pharma, Inc. | Hdl-boosting combination therapy complexes |
| US7767828B2 (en) * | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| PT1689757E (pt) * | 2003-11-12 | 2014-12-09 | Sino Med Internat Alliance Inc | Compostos heterocíclicos de ácido borónico |
| US7317109B2 (en) * | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US7576121B2 (en) * | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US7420059B2 (en) * | 2003-11-20 | 2008-09-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| JP2008500358A (ja) * | 2004-05-25 | 2008-01-10 | メタボレックス インコーポレーティッド | Ｐｐａｒのモジュレーターとしての、二環式の置換されたトリアゾール、およびこれらの調製方法 |
| KR20070036076A (ko) * | 2004-05-25 | 2007-04-02 | 메타볼렉스, 인코포레이티드 | Ｐｐａｒ의 조절제로서의 치환된 트리아졸 및 이의제조방법 |
| US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
| TW200611704A (en) * | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
| US7145040B2 (en) * | 2004-07-02 | 2006-12-05 | Bristol-Myers Squibb Co. | Process for the preparation of amino acids useful in the preparation of peptide receptor modulators |
| US7572805B2 (en) | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
| AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| US7517991B2 (en) * | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
| US7635699B2 (en) * | 2004-12-29 | 2009-12-22 | Bristol-Myers Squibb Company | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
| US7589088B2 (en) * | 2004-12-29 | 2009-09-15 | Bristol-Myers Squibb Company | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
| WO2006076598A2 (en) * | 2005-01-12 | 2006-07-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
| US7361766B2 (en) | 2005-01-12 | 2008-04-22 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
| US7368458B2 (en) * | 2005-01-12 | 2008-05-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
| WO2006078697A1 (en) * | 2005-01-18 | 2006-07-27 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
| ES2319461T3 (es) * | 2005-02-10 | 2009-05-07 | Bristol-Myers Squibb Company | Dihidroquinazolinonas como moduladores de 5ht. |
| WO2006113261A2 (en) | 2005-04-14 | 2006-10-26 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
| US7521557B2 (en) | 2005-05-20 | 2009-04-21 | Bristol-Myers Squibb Company | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
| US7825139B2 (en) * | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| TW200716679A (en) * | 2005-05-26 | 2007-05-01 | Bristol Myers Squibb Co | N-terminally modified GLP-1 receptor modulators |
| US7452892B2 (en) * | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| US7317012B2 (en) * | 2005-06-17 | 2008-01-08 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoind-1 receptor modulators |
| TW200726765A (en) * | 2005-06-17 | 2007-07-16 | Bristol Myers Squibb Co | Triazolopyridine cannabinoid receptor 1 antagonists |
| US20060287342A1 (en) * | 2005-06-17 | 2006-12-21 | Mikkilineni Amarendra B | Triazolopyrimidine heterocycles as cannabinoid receptor modulators |
| US7632837B2 (en) * | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| US7629342B2 (en) * | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
| JP2009502959A (ja) * | 2005-07-28 | 2009-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−１ｈ−ピリド［４，３，ｂ］インドール |
| US7795436B2 (en) * | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
| US7714131B2 (en) * | 2005-09-23 | 2010-05-11 | Metabolex, Inc. | Process for the stereoselective preparation of (−)-halofenate and derivatives thereof |
| US8618115B2 (en) | 2005-10-26 | 2013-12-31 | Bristol-Myers Squibb Company | Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them |
| EP1943215A2 (en) | 2005-10-31 | 2008-07-16 | Brystol-Myers Squibb Company | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods |
| KR101329112B1 (ko) * | 2005-11-08 | 2013-11-14 | 랜박시 래보러터리스 리미티드 | (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법 |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US20070238669A1 (en) * | 2006-01-11 | 2007-10-11 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions |
| US7553836B2 (en) * | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
| CA2569776A1 (en) * | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| CL2007000667A1 (es) * | 2006-03-14 | 2008-03-14 | Ranbaxi Lab Ltd | Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e |
| US20070238770A1 (en) * | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
| EP2021014A1 (en) * | 2006-05-26 | 2009-02-11 | Brystol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| US20080044326A1 (en) * | 2006-07-04 | 2008-02-21 | Esencia Co., Ltd. | Sterilizer for baby products |
| JP2009543773A (ja) * | 2006-07-14 | 2009-12-10 | ランバクシー ラボラトリーズ リミテッド | ＨＭＧ−ＣｏＡレダクターゼ阻害剤の多形体及びその使用 |
| US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| US20100210633A1 (en) * | 2006-10-12 | 2010-08-19 | Epix Delaware, Inc. | Carboxamide compounds and their use |
| WO2008057862A2 (en) | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF |
| MX2009009126A (es) * | 2007-03-01 | 2009-10-28 | Concourse Health Sciences Llc | Isomeros de niacinato de inositol y usos de los mismos. |
| CL2008000684A1 (es) | 2007-03-09 | 2008-08-01 | Indigene Pharmaceuticals Inc | Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica. |
| AR065809A1 (es) | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
| WO2008130951A1 (en) | 2007-04-17 | 2008-10-30 | Bristol-Myers Squibb Company | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors |
| PE20090696A1 (es) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
| EP2147008A2 (en) * | 2007-05-18 | 2010-01-27 | Bristol-Myers Squibb Company | Crystal structures of sglt2 inhibitors and processes for preparing same |
| US20090011994A1 (en) * | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| CN101808995A (zh) * | 2007-07-27 | 2010-08-18 | 百时美施贵宝公司 | 新颖的葡糖激酶激活剂及其使用方法 |
| KR100836960B1 (ko) * | 2007-09-07 | 2008-06-10 | 주식회사 서울제약 | 새로운 나이아신 제어방출형 제제 |
| WO2009076404A1 (en) * | 2007-12-10 | 2009-06-18 | Epix Delaware, Inc. | Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor |
| BRPI0820701A2 (pt) | 2007-12-11 | 2015-06-16 | Cytopathfinder Inc | Composto de carboxamida e seu uso como agonistas do receptor de quimiocina |
| PE20091928A1 (es) * | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos |
| SG10201501882TA (en) | 2009-03-27 | 2015-06-29 | Astrazeneca Ab | Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors |
| CA2780941C (en) | 2009-11-13 | 2018-06-12 | Bristol-Myers Squibb Company | Immediate release tablet formulations |
| ES2689107T3 (es) | 2009-11-13 | 2018-11-08 | Astrazeneca Ab | Formulaciones de tabletas bicapa |
| WO2011060255A1 (en) | 2009-11-13 | 2011-05-19 | Bristol-Myers Squibb Company | Reduced mass metformin formulations |
| TWI562775B (en) | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
| JP2013523894A (ja) | 2010-04-14 | 2013-06-17 | ブリストル−マイヤーズ スクイブ カンパニー | 新規グルコキナーゼアクチベーターおよびその使用方法 |
| PL2590634T3 (pl) | 2010-07-09 | 2016-10-31 | Skojarzony system natychmiastowego / opóźnionego uwalniania leków o krótkim okresie półtrwania, w tym remogliflozyny | |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| TWI631963B (zh) | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法 |
| EP2892897A1 (en) | 2012-09-05 | 2015-07-15 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists |
| US9586900B2 (en) | 2012-09-05 | 2017-03-07 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists |
| PL3489226T3 (pl) | 2012-11-20 | 2021-08-02 | Lexicon Pharmaceuticals, Inc. | Inhibitory kotransportera glukozowo-sodowego 1 |
| US9132117B2 (en) | 2013-06-17 | 2015-09-15 | Kgk Synergize, Inc | Compositions and methods for glycemic control of subjects with impaired fasting glucose |
| US9593113B2 (en) | 2013-08-22 | 2017-03-14 | Bristol-Myers Squibb Company | Imide and acylurea derivatives as modulators of the glucocorticoid receptor |
| WO2016038520A1 (en) * | 2014-09-08 | 2016-03-17 | Sun Pharmaceutical Industries Limited | Processes for the preparation of ticagrelor and its intermediates |
| MX388508B (es) | 2015-02-06 | 2025-03-20 | Intercept Pharmaceuticals Inc | Composicion farmacéutica que comprende un agonista fxr y un fibrato (agonista ppar-alfa). |
| CN107667116A (zh) | 2015-04-30 | 2018-02-06 | 哈佛学院院长及董事 | 治疗代谢病症的抗‑ap2 抗体及抗原结合剂 |
| CA3105626A1 (en) | 2018-07-19 | 2020-01-23 | Astrazeneca Ab | Methods of treating hfpef employing dapagliflozin and compositions comprising the same |
| JP7472139B2 (ja) * | 2018-08-23 | 2024-04-22 | チンタオ、ライジング、バイオテクノロジー、カンパニー、リミテッド | フェノキシカルボン酸化合物およびその医薬用途 |
| MX2021003545A (es) | 2018-09-26 | 2021-05-27 | Lexicon Pharmaceuticals Inc | Formas solidas cristalinas de n-(1-((2-(dimetilamino)etil)amino)-2 -metil-1-oxopropan-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5- trihidroxi-6-(metiltio)tetrahidro-2h-piran-2-il)bencil)fenil)buta namida y metodos para su sintesis. |
| JP2022536060A (ja) | 2019-05-30 | 2022-08-12 | インターセプト ファーマシューティカルズ， インコーポレイテッド | 胆汁鬱滞性肝疾患の処置で使用するためのｆｘｒアゴニストおよびフィブラートを含む医薬組成物 |
| CN119431135B (zh) * | 2025-01-10 | 2025-04-08 | 安徽昊帆生物有限公司 | 4-（4-羟甲基-3-甲氧基苯氧基）丁酸的制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR6679625D0 (pt) * | 1965-05-27 | 1973-10-23 | Merck & Co Inc | Processo para preparar acidos carboxilicos |
| FR1498459A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1965-07-30 | 1968-01-08 |
-
1969
- 1969-04-24 US US819126A patent/US3674836A/en not_active Expired - Lifetime
- 1969-05-19 DE DE19691925423 patent/DE1925423A1/de active Pending
- 1969-05-20 GB GB2576069A patent/GB1225575A/en not_active Expired
- 1969-05-20 FR FR6916281A patent/FR2008997A1/fr active Pending
- 1969-08-12 ZA ZA695769A patent/ZA695769B/xx unknown
- 1969-08-14 AT AT782869A patent/AT291228B/de not_active IP Right Cessation
- 1969-08-21 NL NL696912790A patent/NL148872B/xx not_active IP Right Cessation
- 1969-08-26 BR BR211856/69A patent/BR6911856D0/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB1225575A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1971-03-17 |
| NL148872B (nl) | 1976-03-15 |
| DE1925423A1 (de) | 1969-11-27 |
| FR2008997A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1970-01-30 |
| NL6912790A (en) | 1971-02-23 |
| ZA695769B (en) | 1971-03-31 |
| US3674836A (en) | 1972-07-04 |
| BR6911856D0 (pt) | 1973-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT291228B (de) | Verfahren zur Herstellung neuer α,α-Dimethyl-ω-phenoxyalkansäuren, ihrer Salze oder Alkylester | |
| DE2805488C2 (de) | Tetrahydrofuran-Solvate der Magnesiumhalogenid-Komplexe der α-Brompropionsäure, Verfahren zu deren Herstellung und deren Weiterverarbeitung zur Herstellung von 2-Arylpropionsäuren | |
| EP0034741B1 (de) | Verfahren zur Herstellung eines substituierten Bromfluorbenzols und 3-Brom-4-fluorbenzonitril | |
| CH597199A5 (en) | 3-Phenyl pyridaz-6-ones prodn. | |
| DD239591A5 (de) | Verfahren zur herstellung von 2,4-dichlor-5-fluor-benzoesaeure | |
| EP0068350A1 (de) | Verfahren zur Herstellung von Derivaten der Vinylphosphon- oder Vinylpyrophosphonsäure | |
| CH646679A5 (de) | Verfahren zur herstellung von 1,5-dimethyl-bicyclo(3,2,1)octanol-8. | |
| DE2737481A1 (de) | Verfahren zur herstellung von 2-alkyl- oder 2-cycloalkyl-4-methyl-6-hydroxypyrimidinen | |
| DE2434244A1 (de) | 2-hydroxy-3-(4-alkylphenyl)-3-butensaeureester, verfahren zu ihrer herstellung und deren verwendung | |
| DE2827323A1 (de) | Verfahren zur herstellung von halogenbutenylacrylaten | |
| AT263023B (de) | Verfahren zur Herstellung von neuen Phenothiazinderivaten und ihren Salzen | |
| AT366059B (de) | Verfahren zur herstellung von neuen phosphoniumimidazolverbindungen und von deren saeureadditionssalzen | |
| AT360019B (de) | Verfahren zur herstellung von neuen piperidin- derivaten und deren salzen | |
| AT203495B (de) | Verfahren zur Herstellung von neuen tertiären Aminen | |
| DE1925423C (de) | 2,2-Dimethyl-omega-aryloxy alkansäuren und deren Derivate | |
| CH527833A (de) | Verfahren zur Herstellung von symmetrischen 1,3,5-Trithianverbindungen | |
| AT282628B (de) | Verfahren zur herstellung neuer zimtsaeureamide | |
| AT268256B (de) | Verfahren zur Herstellung von neuen, in 4-Stellung substituierten 2-Alkoxy-5-halogenbenzoesäureestern | |
| DE2926828A1 (de) | Verfahren zur herstellung von n,n'- disubstituierten 2-naphthalinaethanimidamiden und ihren salzen und 2-nphthylimidoessigsaeureestersalze | |
| AT344687B (de) | Verfahren zur herstellung von neuen aldehydolactonen | |
| AT217031B (de) | Verfahren zur Herstellung von neuen Phenylalaninderivaten und deren Salzen | |
| DE1793518A1 (de) | Verfahren zur Herstellung von 1-Vinyltetralolen | |
| AT201612B (de) | Verfahren zur Herstellung von neuen Phosphor- und Thiophosphorsäureestern | |
| AT367394B (de) | Verfahren zur herstellung neuer indanderivate | |
| AT258264B (de) | Verfahren zur Herstellung von 5-(3'-Methylaminopropyl)-5H-dibenzo[a,d] cyclohepten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ELA | Expired due to lapse of time |